Drug Use Disorders Identification Test (DUDIT)

Abstract

The Drug Use Disorders Identification Test (DUDIT) is an 11-item self-administered screening instrument engineered to identify non-alcohol drug-related problems, ranging from hazardous and harmful drug consumption to severe substance use disorders and chemical dependence. Modeled directly on the World Health Organization’s Alcohol Use Disorders Identification Test (AUDIT), the DUDIT was developed at the Karolinska Institutet in Stockholm, Sweden, by Anne H. Berman and colleagues to fill a critical gap in primary care, clinical psychiatry, and criminal justice screening batteries. The instrument captures three conceptual domains across its 11 items: drug consumption patterns (frequency of use, poly-substance use, frequency per typical day, and degree of heavy intoxication; Items 1–4), symptoms of dependence (craving/loss of control, impaired control over cessation, neglect of obligations, and morning drug use/relief use; Items 5–8), and harmful consequences (post-use guilt or remorse, substance-induced physical or psychological injuries, and social or professional expressions of concern; Items 9–11). Responses are scored on a numerical metric yielding a global score between 0 and 44. Psychometric investigations across diverse international cohorts consistently reveal high internal consistency (Cronbach’s α typically ranging between .88 and .94) and robust criterion validity against the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-5) and the International Classification of Diseases (ICD-10/ICD-11). Utilizing empirical cutoff scores of ≥6 for biological men, ≥2 for biological women to detect probable drug-related problems, and ≥25 for both sexes to identify probable drug dependence, the DUDIT exhibits exceptional sensitivity (90%) and specificity (88%). This comprehensive review examines the theoretical foundation, construct architecture, structural validity, reliability parameters, and global clinical applications of the DUDIT.

Keywords

Drug Use Disorders Identification Test, DUDIT, psychometrics, substance use disorder, addiction screening, drug dependence, harmful use, Karolinska Institutet, poly-substance use, clinical assessment, criterion validity

Authors

The Drug Use Disorders Identification Test was formulated, standardized, and validated by a multidisciplinary research cohort based at the Section for Alcohol and Drug Dependence Research within the Department of Clinical Neuroscience at the Karolinska Institutet in Stockholm, Sweden:

• Anne H. Berman, Ph.D. — Associate Professor of Clinical Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; leading authority in behavioral addictions, digital health interventions, and screening methodologies.
• Hans Bergman, Ph.D. — Professor Emeritus of Clinical Psychology and Psychometrics, Department of Clinical Neuroscience, Karolinska Institutet; renowned for foundational contributions to substance use assessment and neuropsychological evaluations.
• Tom Palmstierna, M.D., Ph.D. — Clinical Psychiatrist and Senior Researcher, Department of Clinical Neuroscience, Karolinska Institutet; also affiliated with the Centre for Forensic Psychiatry, Stockholm, and the Norwegian University of Science and Technology (NTNU), specialized in risk assessment, forensic psychiatry, and dual diagnosis.
• Frida Schlyter, M.Sc. — Clinical Psychologist and Psychometrician, Department of Clinical Neuroscience, Karolinska Institutet, contributing extensively to clinical validation trials across the Swedish Prison and Probation Service.

Purpose

The primary clinical and psychometric purpose of the Drug Use Disorders Identification Test (DUDIT) is to provide a rapid, psychometrically sound, low-cost screening instrument capable of identifying individuals on a continuum of non-alcohol drug use, encompassing hazardous use, harmful use, abuse, and physiological or psychological dependence. While the World Health Organization’s AUDIT gained worldwide acceptance as the gold standard for alcohol screening, clinicians and researchers in the late 1990s and early 2000s lacked an identical, parallel self-report tool for illicit substances and non-prescribed psychoactive medications.

Prior instruments targeting drug use either focused strictly on legal ramifications, required extensive diagnostic interview training (e.g., the Addiction Severity Index [ASI] or the Structured Clinical Interview for DSM [SCID]), or focused on lifetime substance exposure without evaluating recent patterns (e.g., the Drug Abuse Screening Test [DAST-20/DAST-10]). The DUDIT was purposefully designed to address these methodological limitations. It restricts its diagnostic temporal window primarily to the preceding 12 months, allowing clinicians to capture dynamic, real-time behavioral patterns and assess therapeutic progress over time.

In clinical practice, the DUDIT serves several critical operational objectives:

• Primary Care Triage: Facilitating rapid identification of non-alcohol drug misuse within general medical outpatient clinics, emergency departments, and community health centers where time constraints preclude lengthier diagnostic interviews.
• Specialized Psychiatric Screening: Identifying comorbidity and dual diagnosis in individuals presenting with primary affective, psychotic, or anxiety disorders, where hidden poly-substance misuse frequently confounds pharmacotherapy and differential diagnosis.
• Correctional and Forensic Evaluation: Screening incarcerated populations, probationers, and parolees to assess treatment readiness, institutional placement needs, and post-release relapse risk.
• Harm Reduction and Brief Intervention: Serving as the structured assessment baseline within Screening, Brief Intervention, and Referral to Treatment (SBIRT) frameworks, providing clear, normative feedback to patients to enhance motivational readiness for change.
• Epidemiological and Clinical Trials Research: Offering a standardized metric of drug misuse severity across observational cohorts and clinical trials assessing pharmacological or behavioral therapies.

Psychological Construct

The DUDIT evaluates the multidimensional construct of substance use pathology as defined by the international psychiatric nosology of the American Psychiatric Association (DSM-IV and DSM-5) and the World Health Organization (ICD-10 and ICD-11). Rather than conceptualizing addiction as an all-or-nothing binary state, the instrument captures drug use along a developmental and behavioral severity continuum spanning three distinct yet interconnected sub-domains:

1. Drug Consumption Behaviors (Items 1–4)

This domain captures the quantitative aspects of substance intake, including frequency, intensity, and multiplicity of exposure:

• Frequency of Ingestion (Item 1): Assesses how often the individual takes non-alcohol drugs over an extended timeframe, serving as an omnibus marker of chemical exposure.
• Poly-Substance Use (Item 2): Quantifies the frequency of consuming multiple psychoactive substances during the same occasion, capturing dangerous pharmacological synergies, elevated toxicity risks, and behavioral impulsivity.
• Dosing Density (Item 3): Measures the number of times drugs are consumed during a typical consumption day, distinguishing between episodic/controlled experimentation and intense, repeated daily redosing.
• Degree of Intoxication (Item 4): Evaluates how frequently the individual becomes heavily influenced by drugs, reflecting central nervous system disruption, impaired motor/cognitive function, and acute behavioral vulnerability.

2. Symptoms of Substance Dependence (Items 5–8)

This domain assesses the core physiological, psychological, and behavioral manifestations of neuroadapted dependence:

• Impaired Control and Compulsion (Item 5): Directly measures drug craving, subjective urgency, and the inability to resist the impulse to ingest substances, reflecting mesolimbic dopamine-driven incentive salience.
• Loss of Volitional Termination (Item 6): Evaluates the inability to stop or moderate drug intake once consumption has commenced, a classic hallmark of the loss of cognitive executive control over consumption.
• Role Obligation Failure (Item 7): Measures the behavioral priority of drug-taking over occupational, familial, academic, and domestic responsibilities, capturing functional impairment and life disruption.
• Withdrawal Alleviation / Morning Use (Item 8): Captures the requirement of taking a drug upon waking following heavy use the day before, serving as a powerful behavioral indicator of physiological withdrawal, tolerance, and neuroadaptation.

3. Harmful Consequences and Interpersonal Impact (Items 9–11)

This domain assesses the deleterious sequelae of substance use on the individual’s mental health, physical safety, and social relationships:

• Affective Distress and Guilt (Item 9): Measures the emotional aftermath of drug consumption, specifically post-use remorse, moral distress, and shame, which often perpetuate self-medication cycles.
• Physical and Mental Trauma (Item 10): Captures bodily injury, psychological harm, overdoses, accidents, or interpersonal violence sustained by the respondent or inflicted upon others as a direct result of drug use.
• Social and Institutional Concern (Item 11): Evaluates whether relatives, friends, healthcare workers, or authorities have expressed overt concern or intervened regarding the individual’s drug consumption patterns, reflecting externally perceptible disruption.

Theoretical Framework

The architectural framework of the DUDIT is deeply rooted in contemporary public health epidemiology, behavioral pharmacology, and neuropsychological models of addiction. Specifically, the test draws upon the following theoretical traditions:

The World Health Organization Screening Paradigm

In 1982, the WHO commissioned the development of the AUDIT to operationalize secondary prevention: identifying hazardous and harmful substance use prior to the emergence of irreversible biomedical sequelae or terminal dependence (Saunders et al., 1993). The DUDIT operationalizes identical conceptual principles for the broader spectrum of illicit drugs and non-prescribed pharmaceutical agents (e.g., cannabis, amphetamines, cocaine, opioids, sedatives, hallucinogens). It posits that early, brief interventions can alter drug-taking trajectories if individuals are detected during the hazardous (pre-dependent) stage.

The Alcohol/Drug Dependence Syndrome Model

The DUDIT incorporates the foundational Alcohol Dependence Syndrome concept pioneered by Edwards and Gross (1976), subsequently extended to drug dependence syndromes across DSM-III-R, DSM-IV, and ICD-10. This model posits that dependence is a distinct psychobiological cluster consisting of:

• Narrowing of the personal drug-taking repertoire;
• Salience of drug-seeking behavior over competing reinforcers;
• Subjective awareness of a compulsion to use (craving);
• Tolerance to pharmacological effects;
• Repeated withdrawal symptoms upon cessation;
• Relief or avoidance of withdrawal symptoms by further use;
• Rapid reinstatement of dependence following periods of abstinence.

Items 5 through 8 directly translate these biological markers into accessible, client-centered self-report indicators.

Neurocognitive and Reinforcement Models of Addiction

Modern translational neuroscience, particularly the work of Nora Volkow and George Koob, conceptualizes addiction as a cyclical, three-stage neurobiological disorder: (1) binge/intoxication, characterized by reward salience and habit formation (assessed by DUDIT Items 1–4); (2) withdrawal/negative affect, characterized by dysphoria, anxiety, and compensatory relief consumption (assessed by DUDIT Items 8 and 9); and (3) preoccupation/anticipation, characterized by compromised prefrontal executive control, intense craving, and neglected obligations (assessed by DUDIT Items 5, 6, and 7). By mapping items directly across this triadic cycle, the DUDIT reflects established neurobiological mechanisms of addiction.

Validity

The psychometric validity of the DUDIT has been exhaustively documented across diverse geographical, clinical, and community populations since its formal introduction.

Criterion-Related and Diagnostic Validity

In the seminal psychometric validation study conducted by Berman et al. (2005), the DUDIT was evaluated against gold-standard psychiatric diagnoses obtained via the Structured Clinical Interview for DSM-IV (SCID-I) within criminal justice facilities, inpatient detoxification centers, and a representative Swedish general population sample (N = 1,061). Using Receiver Operating Characteristic (ROC) analysis, the researchers demonstrated exceptional diagnostic accuracy:

• Detection of Drug-Related Problems (Harmful Use / Abuse): In general population cohorts, an optimal cutoff score of ≥6 for men yielded a sensitivity of 0.90 and a specificity of 0.88 (Area Under the Curve [AUC] = 0.94). For women, due to biological differences in body mass, drug metabolism, and differential societal prevalence, an optimal cutoff score of ≥2 yielded comparable diagnostic performance (sensitivity = 0.90, specificity = 0.88).
• Detection of Severe Drug Dependence: Across clinical detoxification and prison samples, an elevated cutoff score of ≥25 identified severe DSM-IV drug dependence with an empirical sensitivity of 90% and a specificity of 88% (Berman et al., 2005). The mean total score within heavily dependent clinical drug cohorts was 33.2 (SD = 8.0), whereas non-clinical population means remained near zero (M = 0.3, SD = 2.4).

Convergent and Concurrent Validity

The DUDIT demonstrates powerful convergent correlations with existing, widely validated substance misuse measures:

• Correlations with the Drug Abuse Screening Test (DAST-10 and DAST-20) consistently range from r = .78 to .89 across varied adult clinical samples (Hildebrand, 2015; Voluse et al., 2012).
• Strong convergent associations are observed with the drug involvement subscales of the Addiction Severity Index (ASI) (r = .64 to .75) and the World Health Organization’s ASSIST drug-specific domain scores (r > .70).
• Biochemical validation trials utilizing immunoassay urine drug screens (UDS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirm that elevated DUDIT total scores reliably track biological exposure to cannabinoids, amphetamines, cocaine, and illicit opioids.

Discriminant Validity

The DUDIT discriminates cleanly between substance-specific pathology and general psychological distress. In psychometric evaluations among clinical cohorts with primary major depression, generalized anxiety disorder, and schizophrenia, the DUDIT showed low to moderate correlations with the Beck Depression Inventory (BDI-II; r = .21–.29) and the Brief Psychiatric Rating Scale (BPRS; r = .18), proving that high scores reflect genuine substance misuse rather than generalized psychiatric symptomatology.

Reliability

The DUDIT demonstrates robust internal consistency, test-retest stability, and measurement precision across multiple languages, clinical contexts, and demographics.

Internal Consistency

Across validation studies worldwide, the DUDIT consistently achieves internal consistency coefficients well above standard psychometric benchmarks for clinical decision-making:

• In the original Swedish validation cohorts, Berman et al. (2005) reported an overall Cronbach’s alpha (α) of .94 for the full 11-item instrument, with high item-total correlation coefficients ranging from .59 to .84 across all items.
• In a large-scale American evaluation among substance-abusing military veterans and psychiatric outpatients, Voluse et al. (2012) reported an alpha of .93.
• International adaptations yielded similarly high reliability metrics: the Spanish adaptation reported α = .92 (López-Pelayo et al., 2014); the Turkish clinical adaptation reported α = .93 (Evren et al., 2014); the German prison and community sample reported α = .89 (Hildebrand, 2015); and the Brazilian Portuguese validation demonstrated α = .90.
• Modern psychometric evaluations reporting McDonald’s omega (ω) confirm that total scale composite reliability routinely equals or exceeds .92, establishing that the scale functions without structural attenuation or item redundancy.

Test-Retest Reliability and Stability

Temporal stability evaluations demonstrate that the DUDIT yields reliable results over repeated administrations when clinical states remain stable. In test-retest protocols spanning 1 to 3 weeks among outpatient substance users, the instrument yielded an Intraclass Correlation Coefficient (ICC) of .89 to .94, confirming minimal measurement error and high stability across test-retest intervals.

Factor Analysis

Extensive exploratory factor analyses (EFA) and confirmatory factor analyses (CFA) have been conducted across varied global samples to evaluate whether the DUDIT is best conceptualized as a unidimensional scale or a multidimensional instrument.

Unidimensional vs. Two-Factor Models

The structural literature reflects two competing psychometric models:

• Single-Factor General Addiction Model: Berman et al. (2005) originally reported that a single dominant general factor accounted for approximately 64% of the total variance, with all 11 items exhibiting robust standardized factor loadings between .61 and .87. In many clinical and correctional contexts, CFA models of a strictly unidimensional solution demonstrate acceptable to good goodness-of-fit: Comparative Fit Index (CFI) > .94, Tucker-Lewis Index (TLI) > .93, and Root Mean Square Error of Approximation (RMSEA) ≤ .07.
• Two-Factor Correlated Model: Later structural studies (e.g., Hildebrand, 2015; Sinadinovic et al., 2010) identified a two-factor structure that directly mirrors the structural design of the AUDIT:
  • Factor 1: Drug Consumption / Intake Intensity (Items 1, 2, 3, and 4), capturing the quantitative volume, frequency, and poly-substance nature of use.
  • Factor 2: Drug-Related Problems and Dependence Symptoms (Items 5, 6, 7, 8, 9, 10, and 11), capturing loss of control, craving, morning use, guilt, injury, and interpersonal friction.

In comparative CFA trials, the two-factor correlated model often demonstrates superior empirical fit (CFI = .97–.98, TLI = .96–.97, RMSEA = .04–.055, SRMR = .03–.04) with an inter-factor correlation ranging between r = .72 and .84. Despite this empirical dimensionality, researchers and clinicians overwhelmingly utilize the unidimensional global total score (0–44) for screening and risk stratification, as the high inter-factor correlation indicates a single underlying latent continuum of substance misuse severity.

Summary of Typical Item Factor Loadings

Instrument / Measurement Tool

The DUDIT is a structured, 11-item self-administered questionnaire that can also be administered as a clinician-rated structured interview or via secure computerized platforms.

Structural Attributes

• Item Count: 11 items.
• Administration Duration: Approximately 3 to 5 minutes.
• Target Population: Adolescents (aged 14+) and adults across clinical, forensic, and community settings.
• Target Substance Class: All illicit drugs and prescription medications taken for non-medical reasons (excluding alcohol).
• Recall Period: The preceding 12 months for Items 1 through 9; Items 10 and 11 evaluate both past-year occurrence and lifetime occurrence.

Scoring Architecture and Response Options

• Items 1 through 9: Scored on a 5-point Likert scale (0, 1, 2, 3, 4).
  • Item 1: 0 = Never; 1 = Monthly or less; 2 = 2–4 times a month; 3 = 2–3 times a week; 4 = 4 or more times a week.
  • Item 2: 0 = Never; 1 = Less than monthly; 2 = Monthly; 3 = Weekly; 4 = Daily or almost daily.
  • Item 3: 0 = 0; 1 = 1–2; 2 = 3–4; 3 = 5–6; 4 = 7 or more.
  • Items 4–9: 0 = Never; 1 = Less often than once a month; 2 = Every month; 3 = Every week; 4 = Daily or almost every day.
• Items 10 and 11: Scored on a 3-point frequency metric: 0, 2, or 4.
  • 0 = No; 2 = Yes, but not over the past year; 4 = Yes, over the past year.
• Total Score Range: 0 to 44 points.

Clinical Scoring Cutoffs and Interpretive Triage

• Total Score = 0: Indicates complete drug abstinence and zero drug-related risk during the evaluated window.
• Men ≥ 6 points: Probable drug-related problems (hazardous use, harmful use, or mild substance use disorder). Clinical action: brief intervention, harm reduction education, and longitudinal monitoring.
• Women ≥ 2 points: Probable drug-related problems. Because women generally exhibit lower prevalence rates and distinct metabolic vulnerabilities, a lower cutoff provides optimal sensitivity without unacceptable loss of specificity.
• Both Sexes ≥ 25 points: Highly probable drug dependence (moderate-to-severe substance use disorder). Clinical action: immediate referral to specialized addiction medicine services for comprehensive diagnostic evaluation, medical detoxification assessment, and intensive evidence-based psychotherapy (e.g., CBT, contingency management, pharmacotherapy).

Permissions & Fee and Test Year

The Drug Use Disorders Identification Test was formally documented and published in 2003 as a clinical manual by Anne H. Berman, Hans Bergman, Tom Palmstierna, and Frida Schlyter at the Karolinska Institutet, with full peer-reviewed validation published in 2005 in European Addiction Research.

Licensing and Accessibility: The DUDIT is in the public domain and is classified as an open-access screening tool for clinical practice, academic research, and healthcare evaluation. There are no licensing fees, royalty charges, or mandatory user certification costs associated with using the original 11-item instrument. Clinicians, health departments, and academic researchers are permitted to reproduce and administer the questionnaire freely, provided that proper academic attribution is credited to the original authors and the Karolinska Institutet. Commercial re-packaging or distribution within proprietary digital software platforms typically requires formal institutional permission.

References

The following peer-reviewed publications and clinical manuals provide foundational psychometric evidence and historical documentation for the DUDIT:

• Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for use in primary care (2nd ed.). World Health Organization. https://apps.who.int/iris/handle/10665/67254
• Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2003). The Drug Use Disorders Identification Test (DUDIT) Manual. Karolinska Institutet, Department of Clinical Neuroscience, Section for Alcohol and Drug Dependence Research. Stockholm, Sweden.
• Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. European Addiction Research, 11(1), 22–31. https://doi.org/10.1159/000081413
• Edwards, G., & Gross, M. M. (1976). Alcohol dependence: Provisional description of a clinical syndrome. British Medical Journal, 1(6017), 1058–1061. https://doi.org/10.1136/bmj.1.6017.1058
• Evren, C., Ovunc, C., Karabulut, V., Can, Y., & Umut, G. (2014). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) in a Turkish clinical sample of male chemical-dependent inpatients. Dusunen Adam: The Journal of Psychiatry and Neurological Sciences, 27(2), 106–114. https://doi.org/10.5350/DAJPN2014270202
• Hildebrand, M. (2015). The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A review of available evidence. Substance Abuse: Research and Treatment, 9, 7–13. https://doi.org/10.4137/SART.S20138
• López-Pelayo, H., Oliveras, C., Nuño, L., Braddick, F., Segura, L., & Gual, A. (2014). Spanish validation of the Drug Use Disorders Identification Test (DUDIT). Adicciones, 26(4), 312–320. https://doi.org/10.20882/adicciones.3
• Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R., & Grant, M. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction, 88(6), 791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x
• Sinadinovic, K., Berman, A. H., Hasson, D., & Wennberg, P. (2010). Internet-based assessment and self-monitoring of problematic alcohol and drug use. Addictive Behaviors, 35(5), 464–470. https://doi.org/10.1016/j.addbeh.2009.12.021
• Voluse, A. C., Gioia, C. J., Sobell, L. C., Dum, M., Sobell, M. B., & Simco, E. R. (2012). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient and residential settings. Addictive Behaviors, 37(1), 36–41. https://doi.org/10.1016/j.addbeh.2011.08.006

13. Items of the Scale (Questionnaire)